Health, Education & Government Life Sciences & Pharma Cell & Gene Therapy

Patient Coordination

Regulated development and commercialization journeys where clinical, quality, and market access align.

CATO Research Services PSI CRO ICON Parexel
Inside this journey
  1. Pre-Discovery

    Align the room on outcomes, decision process, and constraints before deeper discovery.

    1. Stakeholder Alignment

      Confirm decision roles, timelines, escalation paths, and the clinical stakeholders needed to protect patient treatment windows.

      Alignment Questions

      Quick Grounding — Who You Are and What You Own

      • What's your primary role and title for the programs you manage? Options: Director, Clinical Operations, Head of Patient Services, Program Manager, Clinical Project Lead, Other
      • Which therapeutic area or program type are we discussing today? Options: Autologous cell therapy, Allogeneic cell therapy, Gene therapy, Rare disease specialty program, Combination/other
      • Tell us at a glance: how many active patients per month are you coordinating today (ballpark)? Options: 1–5, 6–25, 26–100, 100+
      • Is this program in clinical development, transitioning to commercial, or already commercial? Options: Clinical trials (early), Clinical trials (late), Transitioning to commercial, Commercial
      • Briefly describe one recent scheduling or coordination issue that felt urgent—what happened in two or three sentences?

      What Keeps You Up at Night About Treatment Timelines?

      • If you had to name the single scheduling failure most likely to derail a patient’s treatment window, what would it be?
      • How often do you experience events that threaten a treatment window (no-shows, missed apheresis, site non-responsiveness)? Options: Weekly, Monthly, Quarterly, Rarely/never
      • Which of the following failure modes do you see most often? (Select all that apply) Options: Patient no-shows, Pre-treatment clearance delays, Apheresis timing missed, Site scheduling conflicts, Manufacturing slot mismatch, Data/timeline mismatches
      • When those failures occur, which immediate consequence hits first (operational, clinical, emotional)? Options: Manufacturing delay, Patient anxiety/withdrawal, Rescheduling cascade, Additional cost, Regulatory reporting risk
      • How long has this pattern been happening at your program? Options: Less than 6 months, 6–12 months, 1–3 years, 3+ years

      When Systems Fail a Patient — A Deeper Look

      • Think of the last time a patient’s treatment window was at real risk—what failed first?
      • Which stakeholders were involved in that breakdown? (Select all that applied) Options: Local treatment center/site staff, Manufacturer scheduling team, Logistics/transport, Internal clinical ops, Third‑party coordinators, Patient/caregiver
      • Which communication channels were used and which one failed to deliver? (Select all used; then tell us which failed) Options: Phone call, Secure email, EHR/portal message, Vendor portal, Text/SMS, In-person
      • Describe the moment you realized escalation was required—what indicators tipped you off?
      • How quickly do you typically resolve these incidents once identified? Options: Within hours, Same day, 1–3 days, More than 3 days

      Who Holds the Keys — Roles, Responsibilities, and Gaps

      • If you had to pick one role that most often prevents missed milestones, who would it be—and why does that person matter?
      • Which of these functions are clearly owned inside your organization today? (Select all that apply) Options: Patient scheduling, Site liaisoning, Manufacturer slot coordination, Travel & lodging logistics, Escalation management, Data/timeline reconciliation
      • Where do you see the biggest accountability gaps right now? Options: Between sponsor and manufacturer, Between site and sponsor, Between clinical ops and patient services, Third-party coordination handoffs, Other
      • What is your current coordinator model? Options: Dedicated coordinator per patient, Shared coordinator across sites, Centralized coordination team, Hybrid (dedicated + central), Ad hoc/rotational
      • Approximately what coordinator-to-patient ratio feels sustainable for your program? Options: 1:1–2, 1:3–5, 1:6–10, 1:11+
      • Which training or experience gaps do you see most often in coordinators that contribute to issues?

      What 'Zero Missed Windows' Actually Requires

      • If achieving 'zero missed windows' were realistic, what single daily habit or capability would have to change in your operations?
      • Which metrics would you use to prove a coordination solution is working for you? (Select top indicators) Options: On-time collections, On-time infusions, Percent missed windows, Time-to-resolution for escalations, Patient satisfaction/NPS, Site response time
      • What percentage change in those metrics would make you convinced the program is successful? Options: 10–25%, 26–50%, 51–75%, >75%
      • How often do you need performance reporting (and in what format) to feel in control? Options: Daily dashboards, Weekly summary, Monthly review, Quarterly deep-dive
      • Describe one small, testable improvement you would accept as proof-of-concept (pilot) success.

      Trade-offs We Live With (and the Risks They Carry)

      • What current manual workaround do you dread the most—one that you know is fragile but keeps things moving?
      • Which of the following trade-offs are you actively making today? (Select all that apply) Options: Faster fixes at higher cost, Spot fixes over system changes, Using multiple disconnected tools, Relying on informal relationships with sites, Understaffing coordination roles
      • How often do those workarounds produce a near-miss that required an all-hands response? Options: Very often, Often, Occasionally, Rarely
      • What would be the hardest part about removing those workarounds—culture, budget, technology, or something else? Options: Culture/people, Budget/finance, Technology/integration, Vendor alignment, Regulatory/quality concerns
      • If you could eliminate one trade-off immediately without cost penalty, which would you choose and why?

      Deciding to Change — What Would Make You Say Yes Today?

      • What's the single operational guarantee that would make you sign a coordination agreement today?
      • Which commercial flexibility matters most when choosing a partner? Options: Pilot-first pricing, Pay-for-performance, Fixed monthly fee, Scale-based pricing, Custom contracting
      • What integrations or data feeds are non-negotiable for you? (Select all required) Options: Manufacturer scheduling API, Site EHR integration, Patient portal SSO, Logistics partner tracking, Clinical trial management system
      • Who are the decision stakeholders we would need to convince, and what's their main concern? (List names/roles and a one-line concern for each)
      • Realistically, what's your decision timeline for a coordination partner? Options: Immediate (weeks), 1–3 months, 3–6 months, 6+ months, Undecided
      • What are the top three internal blockers to procurement or pilot approval we should anticipate?
      • Would you be open to a focused pilot that guarantees a defined improvement in a single KPI? If yes, which KPI would you prefer to pilot against? Options: On-time collections, On-time infusions, Reduced missed windows, Faster escalation resolution, Improved patient satisfaction
    2. Current State Mapping

      Document the end-to-end treatment workflow, failure modes (no-shows, missed apheresis, site non-responsiveness), and system touchpoints.

      Current State

      Start Here: A Quick Program Snapshot

      • What is your title and the program (trial/commercial) you currently manage? Options: Clinical Operations Director, Patient Services Lead, Program Manager, Site Operations Lead, Other
      • Which therapy modalities are you coordinating today? Options: Autologous cell therapy, Allogeneic cell therapy, Gene therapy, Rare disease treatment, Other
      • How many active patients are in the current cohort you support? Options: 1–5, 6–20, 21–100, 100+
      • How many distinct clinical sites (collection + infusion) does a typical patient interact with? Options: 1, 2, 3–5, 6+
      • Briefly map your typical end-to-end treatment timeline (key milestones and typical durations).
      • What systems or tools do your team use every day to track patient milestones? Options: EHR/EMR, CTMS, Manufacturer portal, Proprietary scheduler, Spreadsheets, Patient portal, Other

      Where Timelines Turn Into Crises

      • What is the single recurring failure that most often converts a planned treatment window into a crisis?
      • Roughly how often do those failures occur across your patients? Options: <1% of patients, 1–5%, 6–15%, 16–30%, 30%+
      • Which failure modes do you see most frequently? Options: Patient no-shows, Missed apheresis, Delayed lymphodepletion, Site non-responsiveness, Transport/logistics delays, Manufacturing delay/hold, Other
      • Share one anonymized example of a recent failure and the cascading impacts it created (manufacturing loss, reschedule complexity, patient harm).
      • Who typically first identifies the issue when a timeline breaks? Options: Site coordinator, Sponsor clinical ops, Manufacturer rep, Patient/caregiver, Logistics provider, Other
      • From detection to a concrete remediation plan, how long does your team typically take? Options: <4 hours, 4–24 hours, 1–3 days, >3 days

      When the Phone Goes Silent: Site Communication and Escalation

      • How often do sites go silent at critical moments, and what do you believe is the root cause?
      • Which communication channels do sites prefer—and which ones most often fail when speed matters? Options: Phone, Email, EHR messages, Vendor portal, SMS/text, Other
      • Do you have a documented escalation path for site non-responsiveness? Options: Yes — formal SOP, Informal process (email/Slack), No defined escalation, Partially documented
      • How quickly are non-responses escalated under your current process? Options: Within 1 hour, 1–4 hours, 4–24 hours, Not tracked
      • Who must be looped in for clinical decisions if a site cannot perform a scheduled step on time? Options: PI/site medical director, Sponsor clinical lead, Manufacturer medical affairs, Patient coordinator, Patient/caregiver, Other
      • Describe one scenario where escalation successfully prevented a missed window and one where it failed—what differed in each case?

      If We Aimed for Zero Missed Windows — What Would Change?

      • If zero missed treatment windows were non-negotiable, what current behaviors or processes would you have to stop tolerating today?
      • Which measurable success signals would prove to you the program is operating without missed windows? Options: On-time apheresis, On-time lymphodepletion, On-time infusion, Zero missed windows, No product expirations, High patient satisfaction, Reduced reschedules
      • What specific thresholds do you use (or would you use) to define 'on-time' for each milestone?
      • How do missed milestones today affect patient experience, caregiver trust, and retention?
      • Which constraints would be hardest to change to achieve zero missed windows? Options: Site staffing, Patient travel/logistics, Transport reliability, Manufacturing capacity, Regulatory timing, Budget/resources, Other
      • What cadence and type of reporting (alerts, dashboards) would make you confident that milestones are safe day-to-day? Options: Real-time alerts, Daily operational dashboard, Weekly executive summary, Case-level timeline views, Automated SLA breach notifications, Other

      Who’s In the Hot Seat When Things Go Wrong?

      • When timelines break and product/slot risk emerges, who truly owns the decision to delay, reschedule, or proceed—and is that ownership crystal clear?
      • Which decision roles exist today (who can approve reschedule, cancel, escalate to manufacturer, change lymphodepletion timing)?
      • Do you have SLAs or required response times tied to each role for critical issues? Options: Yes — formal SLAs, Informal expectations, No SLAs, Partially defined
      • How are handoffs and ownership between coordinator, site, manufacturer, and sponsor tracked or verified? Options: Automated system logs, Email trails, Spreadsheets, Phone call logs, Other
      • How often do disputes about responsibility create delays in remediation? Options: Never, Rarely, Sometimes, Often, Almost always
      • What would make taking ownership and escalating feel less risky or politically fraught within your organization?

      The Technology That Holds the Journey Together (or Lets It Fall Apart)

      • If one system fails right now, which failure would create the most immediate patient risk and why?
      • Which systems are currently part of your tech stack for coordination and tracking? Options: EHR/EMR, CTMS, Manufacturer portal, Proprietary scheduler, Patient-facing portal, Spreadsheets, Other
      • Do you have real-time integrations from sites/manufacturers feeding a single operational view? Options: End-to-end real-time integration, Partial near-real-time feeds, Manual uploads/syncs, No integrations today
      • Which data elements must be real-time to prevent missed windows? Options: Appointment confirmations, Patient travel status, Apheresis completion timestamps, Manufacturing ETA, Chain-of-custody events, Lab result arrivals, Other
      • How do coordinators currently get alerted to at-risk patients (and how reliable are those alerts)? Options: Email, SMS, Portal/ dashboard alert, Phone call, No automated alerts, Other
      • What privacy, security, or integration constraints would we need to navigate for deeper system access?

      If We Tried One Pilot — What Would It Take to Win?

      • What single change tested in a focused pilot would most convincingly prove we can eliminate the most critical missed milestones?
      • What pilot scale would you consider reasonable to demonstrate impact (patients/sites)? Options: 1 patient / 1 site, 3–5 patients / 1–2 sites, 10–20 patients / multiple sites, Larger enterprise pilot
      • Which objective success metrics would make you approve expansion? Options: % reduction in missed windows, Time-to-remediation, Patient NPS/experience, Site response time, Number of escalations, Cost per patient, Other
      • Who internally must be engaged for a pilot to proceed and roughly how much time would they need to commit?
      • What budget range and contracting timeline would you expect for a pilot this quarter? Options: <$50k, $50k–$200k, $200k–$500k, >$500k, Unsure
      • What are the non-negotiable acceptance criteria you’d require before scaling beyond a pilot?
  2. Outcome Discovery

    Define target outcomes, measurable success signals (on-time collections/infusions, zero missed windows), and scalability requirements.

    Discovery Questions

    Setting the Table: A Quick Snapshot of Your Program

    • Which stage best describes your program today? Options: Pre-clinical/Planning, Early clinical (Phase 1), Late clinical (Phase 2/3), Commercial launch, Maintenance/scale
    • Roughly how many patients per month pass through the coordinated pathway today? Options: 1–5, 6–20, 21–50, 51–200, 200+
    • Which therapy types are you coordinating right now? (select all that apply) Options: Autologous cell therapy, Allogeneic cell therapy, Gene therapy, Enzyme replacement/rare disease, Other
    • Describe your current coordination model in one sentence (who owns scheduling, who escalates).
    • Which systems are you currently using to track patient milestones? Options: EHR/EMR, Sponsor/MFG portal, Proprietary coordination tool, Spreadsheets/email, Other

    The Stakes: What Happens When a Window Is Missed?

    • If a single missed treatment window could cost a manufacturing slot or patient safety, how would that change how you prioritize coordination?
    • How often do missed windows or manufacturing delays occur in your program? Options: Weekly, Monthly, Quarterly, Rarely/Never, Not tracked
    • Which outcomes have you already observed when windows are missed? (select all that apply) Options: Product expiration/loss, Manufacturing delay, Patient drop-out, Safety/clinical risk, Regulatory reporting, Operational cost overrun
    • Tell us about a specific recent case where a scheduling breakdown had significant downstream impact—what happened and why?
    • How do these events typically affect stakeholder confidence (internal teams, sites, patients)? Options: Severely erodes trust, Creates short-term friction, Managed but resented, Minimal impact

    What’s Quietly Breaking — The Real Failure Modes

    • What recurring operational failure do teams act like is 'normal' but actually causes the most risk?
    • Which of these failure modes occur most often in your workflow? (select all that apply) Options: Patient no-shows, Missed apheresis/infusion prep, Site non-responsiveness, Travel/logistics failures, Documentation/consent gaps, Slot booking mismatches
    • When one of those failure modes happens, how do you discover it first? Options: Site notifies, Coordinator detects, Manufacturer flags, Patient reports, System alert
    • How long does it typically take to detect and resolve a failure mode from first sign to resolution? Options: <4 hours, 4–24 hours, 1–3 days, 3+ days, Unknown
    • In your experience, what’s the single root cause that, if fixed, would eliminate the most downstream failures?

    Metrics That Matter — What You’d Put on the Dashboard

    • Would you trade a small improvement in 'on-time' metrics for a big reduction in patient stress? Why or why not?
    • Which success signals should we track to prove value? (pick up to 5) Options: On-time collections, On-time infusions, Zero missed windows, Patient satisfaction score (NPS), Coordinator response time, Time-to-resolution for conflicts, Manufacturing slot utilization, Site escalation compliance
    • What are your current baselines for the top 3 KPIs you care about?
    • What thresholds would make you comfortable calling the program a success? Options: Conservative (small improvement), Moderate (measurable improvement), Ambitious (industry-leading), Unsure—need to agree
    • How frequently do you need reporting to feel confident—real-time, daily, weekly, or monthly? Options: Real-time/dashboard, Daily, Weekly, Monthly

    If Volume Doubled Tomorrow: Where Would You Fall Over?

    • If you had to double patient throughput in 90 days, what would break first and why?
    • Which constraints limit scale today? (select all that apply) Options: Coordinator headcount, Site capacity/scheduling, Tech integrations/API limits, Training/onboarding time, Travel/logistics capacity, Regulatory/compliance processes
    • What coordinator-to-patient ratio do you consider safe for current clinical complexity? Options: 1:5, 1:10, 1:15, 1:20, Varies by therapy
    • How quickly can you add new coordination headcount and get them fully productive? Options: <2 weeks, 2–6 weeks, 6–12 weeks, 12+ weeks, Cannot scale quickly
    • Describe any single-system or manual bottleneck that consistently constrains capacity.

    Who's Accountable at Critical Moments?

    • When a time-sensitive escalation occurs, who currently has authority to make binding changes (slots, travel, clinical schedule)? Options: Site PI/lead, Sponsor operations, Manufacturer operations, Patient coordinator, Other
    • Do escalation paths include after-hours decision ownership? If so, who covers it? Options: Yes—dedicated on-call, Yes—rotating staff, No—depends on site, No formal after-hours plan
    • How clearly documented are decision rights and escalation timelines for each milestone (apheresis, lymphodepletion, infusion)? Options: Fully documented, Partially documented, Informal, Not documented
    • Share an example of a time escalation failed—what decision gap caused the issue?
    • Which parties must sign off on acceptance tied to clinical milestones? Options: Sponsor/clinical ops, Manufacturer, Site PI, Regulatory rep, Other

    Patient Experience Signals We Shouldn’t Ignore

    • When a patient walks away satisfied from a coordinated therapy journey, what emotion or experience did we deliver?
    • What patient-facing channels work best for your population? (select all that apply) Options: Portal messages, SMS/text, Phone calls, Email, Caregiver outreach, In-person coordination
    • Which patient experience metrics do you currently capture? Options: NPS, Satisfaction surveys, Time-to-contact, Retention/continuation, Do not capture
    • How do coordination failures affect patient anxiety and adherence in your programs? Options: Greatly increases anxiety, Moderately increases, Minimal effect, Unknown
    • What expectations do patients and caregivers have for update frequency and clarity? Options: Multiple daily updates, Daily, Every milestone, Only when action needed, Varies by patient

    Trade-offs, Red Lines, and Non-Negotiables

    • What would cause you to terminate a coordination partnership even if performance metrics improved?
    • Which contractual or compliance items are absolute requirements? (select all that apply) Options: Data residency, Business associate agreement (BAA), Clinical liability limits, Audit rights, Regulatory reporting support
    • How much pilot tolerance do you have for initial failure while processes stabilize? Options: Zero tolerance, Small tolerance (1–2 cases), Moderate tolerance (pilot cohort), High tolerance—iterative approach
    • Describe any legal, commercial, or ethical constraints that would limit automation or escalation (e.g., patient consent, site policies).
    • Are there internal stakeholders who will veto changes regardless of operational improvement? Who are they?

    If Success Lived on a Scoreboard, What Three Numbers Matter?

    • Pick the three metrics you'd want on your weekly dashboard (choose up to 3) Options: % On-time collections, % On-time infusions, Missed treatment windows (count), Patient NPS, Coordinator response SLA compliance, Time-to-resolution (hours), Manufacturing slot utilization
    • What target value would represent an acceptable week for each chosen metric?
    • Who in your organization will ultimately sign off that these targets are met? Options: Director of Clinical Ops, VP/Head of Patient Services, Manufacturing Ops Lead, Clinical Safety/QA, Other
    • How would you prefer exceptions or near-misses to be surfaced—automated alerts, daily report, weekly review, or real-time phone escalation? Options: Automated alerts, Daily report, Weekly review, Real-time phone escalation, Combination
    • What timeline feels realistic to reach your 'acceptable' targets (pilot duration to scale)? Options: 30 days, 60–90 days, 3–6 months, 6–12 months

    Small Tests That Build Confidence — What Would You Pilot?

    • What single experiment would you be willing to run in the next 30–90 days to test outcome improvements?
    • What sample size and therapy complexity level would make a pilot meaningful for you? Options: 1–5 patients, single-site, 6–20 patients, multi-site, 21–50 patients, mixed complexity, Other
    • Which data feeds and integrations must be live for the pilot to be valid? (select all that apply) Options: Slot booking API, Site scheduling system, Manufacturer timeline feed, Patient portal access, Travel booking integration
    • Who are the key stakeholders that must be engaged for a pilot to proceed (name roles)?
    • What acceptance criteria would you use at pilot end to decide whether to expand? Options: Metric-based thresholds met, Positive stakeholder feedback, No critical safety events, All of the above, Other
  3. Solution Experience

    Walk through patient- and site-level scenarios showing how coordinators, portal visibility, and escalation protocols prevent missed milestones.

    Experience Meetings

    • Current State Confirmation & Prework Review
    • Consequence & Risk Quantification
    • Patient-Level Scenario Walkthroughs (Diagnosis → Proof → Validation)
    • Site-Level Workflow & Escalation Protocols
    • Validation & Pilot Sign-off Workshop
    • Legal/commercial to draft SLA language reflecting agreed response times for inclusion in the scope document.
    • Sponsor to confirm financial assumptions and provide cost-per-incident inputs for modeling.
    • Host to produce a one-page consequence summary linking failure modes to costs and risks.
    • Operations to propose target success thresholds for on-time collections/infusions and share with stakeholders.
    • One-sentence Future State
    • Validate that coordinator interventions and portal alerts would prevent missed milestones in the provided patient scenarios.
    • Confirm that each remediation step ties directly to the quantified consequences and success signals.
    • Identify any gaps in SOPs, portal alerts, or escalation timing that require adjustment before pilot.
    • Coordinators to produce a step-by-step SOP for each demonstrated scenario with exact timestamps and owner handoffs.
    • Product team to provide interactive portal mockups with the specific alert thresholds and views used in the walkthrough.
    • Clinical ops to confirm that the scenarios accurately reflect patient clinical constraints and approve described mitigations.
    • Review Site Roles & SLAs
    • Agree on a time-bound escalation tree with named owners and contact information.
    • Confirm SLA targets for site responses and manufacturer integrations that align to success signals.
    • Produce a runbook outline and communication templates for all site-level incidents.
    • Operations to publish the escalation tree with named contacts, response times, and backup contacts.
    • Introductions & Objectives
    • Host to create the site communication runbook and share editable templates for sponsor review.
    • Recap: Current State, Consequence, Future State
    • Formal sign-off to proceed to a pilot/dry-run or a clear list of remaining conditions for sign-off.
    • Finalized acceptance criteria and success signals to evaluate pilot outcomes.
    • Assigned owners and scheduled dates for the pilot with required resources committed.
    • Sponsor to provide written sign-off or a list of remaining sign-off conditions within 3 business days.
    • Operations to schedule the dry-run pilot, notify selected sites, and publish the pilot runbook.
    • Product to enable portal features and alert thresholds required for the pilot and provide access to pilot users.
    • Coordinators to complete scenario SOPs and confirm training is scheduled before the pilot start.
    • A single, validated one-sentence current state that all participants accept.
    • All required artifacts (timelines, incidents, contacts) confirmed and owned by named participants.
    • Failure modes and metrics to be used in the Solution Experience are finalized.
    • Schedule and participants for scenario walkthrough meetings are agreed.
    • Sponsor to deliver 3 redacted patient timelines and last 12 months of missed-milestone incidents (deadline: 3 business days).
    • Clinical ops to assign site SMEs and populate the site contact matrix in the shared workspace.
    • Host (coordination team) to prepare role-based portal screenshots and coordinator SOP draft for walkthroughs.
    • Restate Agreed Current State
    • Explicit, quantified consequences for each prioritized failure mode (time, cost, clinical risk).
    • A ranked list of failure modes to be tested in the Solution Experience based on consequence.
    • Clear, measurable success signals that define the desired future state.
    • One-sentence Current State
    • Historical Impact Review
    • Review Learnings from Walkthroughs
    • Walkthrough — Site Non-response Escalation
    • Scenario 1 — Missed Pre-treatment Medication
    • Validation Checkpoint 1
    • Financial & Clinical Consequence Modeling
    • Review Pre-work Deliverables
    • Acceptance Criteria & Success Signals
    • Walkthrough — Apheresis Slot Conflict & Manufacturer Integration
    • Prioritize Failure Modes by Consequence
    • Scenario 2 — Patient No-show Due to Travel
    • Escalation Tree & Timing Drilldown
    • Pilot Cohort & Schedule
    • Confirm Failure Modes
    • Authority, Decision Rights & Exceptions
    • Agree Target Success Signals
    • Data & Metrics Check
    • Validation Checkpoint 2
    • Decision & Sign-off
    • Communication Runbook & Templates
    • Finalize Walkthrough Participants & Roles
    • Next Steps & Owners
  4. Solution Scope

    Define included coordination services, responsibilities, integrations, SLAs, and verification criteria for each treatment milestone.

    Scope Configuration

    • Assign Dedicated Patient Coordinator
    • Provision Patient Portal Access
    • Book Apheresis and Infusion Appointments
    • Reserve Patient Travel and Lodging
    • Integrate Manufacturer Slot Booking Feed
    • Real-Time Treatment Milestone Tracking
    • Operate 24/7 Patient Clinical Hotline
    • Provide Day-of-Treatment Onsite Support
    • Execute Insurance Prior Authorization Submissions
    • Coordinate Chain-of-Custody for Shipments
    • Manage Pre-Treatment Medication and Supply Delivery
    • Run Escalation Protocols for Treatment Conflicts

    Scope Questions

    Assign Dedicated Patient Coordinator

    • What patient-to-coordinator ratio do you expect at launch? Options: 1:1 (dedicated per patient), 1:2-5, 1:6-10, 1:10+
    • Should coordinators be permanently assigned to a patient or operate as a pooled team with handoffs? Options: Permanently assigned (single coordinator per patient), Pooled team with primary contact and backups, Hybrid model
    • Which coordinator qualifications are required (select all that apply)? Options: RN with oncology/hematology experience, Clinical research coordinator experience, Cell/Gene therapy-specific experience, Logistics/operations experience, Patient navigation or social work background, Other
    • What language(s) must coordinators fluently support? Options: English, Spanish, Mandarin, Other
    • Specify any additional coordinator responsibilities you require (open text).
    • What hours and days should coordinators be reachable for routine coordination? Options: Standard business hours (M-F), Extended hours (early/late), Weekends included, 24/7 coverage required

    Provision Patient Portal Access

    • Which user groups need portal access? Options: Patient, Caregiver, Dedicated coordinator, Site staff (nurse/clinic), Manufacturer, Sponsor/clinical operations
    • Which portal features are required at go-live? Options: Schedule visibility, Two-way secure messaging, Document upload/download (consents, instructions), Real-time milestone status, E-signature for forms, Billing/payment view
    • Is single sign-on (SSO) or enterprise identity provider integration required? Options: Yes - SSO required, No - separate portal accounts, Optional
    • Are accessibility (ADA) or localization (multi-language) requirements mandatory? Options: Yes - ADA compliance required, Yes - multi-language required, Both ADA and multi-language required, No
    • How should patient onboarding to the portal be handled? Options: Automated email invite, Phone-assisted setup by coordinator, In-person site-assisted setup, Combination
    • If multi-language or custom content is required, please list required languages and content types.

    Book Apheresis and Infusion Appointments

    • Approximately how many apheresis and infusion appointments do you anticipate per month? Options: 1-10, 11-50, 51-200, 200+
    • How geographically distributed are treatment sites? Options: Single metropolitan area, Multi-city domestic, National (many regions), International
    • Do you require direct integration with site scheduling systems (e.g., EMR schedulers)? Options: Yes - real-time integration, Yes - batch/calendar exports, No - manual booking by coordinator
    • What level of appointment flexibility is acceptable for critical milestones (fixed windows vs flexible rescheduling)? Options: Fixed slot required (no flexibility), Limited flexibility with approved windows, Flexible scheduling allowed
    • What confirmation cadence and methods do you expect for appointments? Options: 72 hours + phone/SMS, 48 hours + email, 24 hours + SMS/phone, Multiple reminders (72/24/2 hours)
    • Are after-hours or weekend appointment options required for apheresis/infusion? Options: Yes - evenings/weekends required, Optional - based on patient need, No

    Reserve Patient Travel and Lodging

    • Which travel and lodging elements should we manage? Options: Air travel, Ground transportation (ambulatory and non-ambulatory), Hotel/lodging, Caregiver travel and lodging, Local transit (rideshare/taxis)
    • What booking policy should we follow when balancing patient preference vs cost/approval? Options: Patient preference prioritised, Cost-effective vendor by default, Sponsor-approved policy required, Hybrid/threshold-based
    • What typical travel scope applies (local same-city, domestic flights, international)? Options: Local/same-city, Domestic flights, International travel, Mixed
    • Do travel arrangements require pre-authorization or expense approval workflows? Options: Yes - pre-authorization required, No - coordinator can book directly, Vary by cost threshold
    • Are there preferred travel vendors, corporate travel management (TMC) or vendor integrations to use? Options: Use sponsor/vendor-provided TMC, Use our travel partners, No preference, Other
    • Who is financially responsible for travel and lodging (sponsor, patient, insurer, hybrid)? Options: Sponsor, Patient (reimbursement), Insurer, Hybrid

    Integrate Manufacturer Slot Booking Feed

    • Which technical feed types does the manufacturer support for slot booking? Options: REST API (JSON), SOAP API, SFTP/CSV feed, HL7/FHIR, Manual spreadsheet exchange
    • What frequency of slot updates is required? Options: Real-time (push), Near real-time (polling every 5-15 minutes), Hourly, Daily
    • Which core data elements must be exchanged from the manufacturer? Options: Slot ID/time, Slot capacity/availability, Product lot/expiry constraints, Pre-qualification flags, Cancellation/rebooking notices, Other
    • What authentication/network requirements must be supported (select all that apply)? Options: OAuth2, API key, IP allowlist/VPN, SFTP credentials, None (manual)
    • Will a sandbox/test environment be provided by the manufacturer for integration testing? Options: Yes, No, Unknown - need to confirm
    • What is your target timeline to complete manufacturer feed integration? Options: <2 weeks, 2-4 weeks, 4-8 weeks, 8+ weeks

    Real-Time Treatment Milestone Tracking

    • Which milestones must be tracked in real-time (select all that apply)? Options: Enrollment consent, Apheresis scheduled/completed, Shipment pickup/delivery, Manufacturing start/complete, Lymphodepletion start, Infusion scheduled/completed, Adverse events
    • How should milestone updates be delivered to stakeholders? Options: Web dashboard, Automated email, SMS/push notifications, API/webhook, Portal messages
    • What SLA do you require for reflecting milestone status changes in the system? Options: Near real-time (<5 minutes), Within 1 hour, Same business day, End of day
    • Which stakeholders must have visibility to milestone tracking? Options: Patient/caregiver, Coordinator, Site staff, Manufacturer, Sponsor/ops
    • Do you require audit trails and exportable reports for milestones for regulatory review? Options: Yes - full audit trail required, Yes - summary reports only, No
    • What uptime or availability SLA do you require for the tracking system? Options: 99.9% (enterprise), 99% (standard), Business hours availability, Other

    Operate 24/7 Patient Clinical Hotline

    • Do you require a 24/7 clinical hotline or extended business-hours coverage? Options: 24/7 clinical hotline, Extended hours (nights/weekends), Business hours only
    • What languages must hotline staff support? Options: English, Spanish, Other
    • What average monthly call volume do you anticipate to size staffing? Options: <50 calls, 50-200 calls, 200-500 calls, 500+ calls
    • Should the hotline provide clinical triage by licensed clinicians or scripted navigation by coordinators? Options: Licensed clinician triage (RN/NP), Scripted coordinator triage, Hybrid/escalate to clinician
    • Are automatic escalation rules required from hotline to sponsor/manufacturer/site for specific triggers? Options: Yes - clinical escalation, Yes - logistical escalation, No
    • Do you require integration of hotline logs with EHR or sponsor case systems? Options: Yes - direct integration, Yes - periodic exports, No

    Provide Day-of-Treatment Onsite Support

    • Which onsite roles do you require on day-of-treatment? Options: Dedicated coordinator, Registered nurse (RN), Logistics lead/courier liaison, Clinical research nurse, Other
    • For each site, how many day-of-treatment staff days do you expect per patient/event? Options: Half-day, 1 full day, 2 days (pre/post), Multiple days
    • Will onsite staff require site credentialing, EMR access, or badge issuance? Options: Yes - credentialing/EMR access needed, Yes - badge access only, No
    • Do you require a written onsite SOP and checklists to be followed by staff? Options: Yes - standardized SOP/checklist required, Optional - provide guidance only, No
    • Are travel, lodging and per-diem for onsite staff managed by sponsor or coordinator organization? Options: Sponsor manages, Coordinator org manages, Hybrid
    • Please describe any clinical tasks onsite staff must perform beyond coordination (e.g., sample handling, bedside support).

    Execute Insurance Prior Authorization Submissions

    • Do apheresis/infusion or related services typically require prior authorization for your patient population? Options: Yes - commonly required, Sometimes - depends on payer, No - not required
    • Which payer types are most common for your patients? Options: Commercial, Medicare, Medicaid, Self-pay/uninsured, Other
    • Do you require full prior auth submission handling including appeals and denials management? Options: Yes - full lifecycle (submissions + appeals), Yes - submissions only, No - sponsor/payer handles appeals
    • What turnaround expectations do you have for prior authorizations? Options: 48-72 hours, 5-10 business days, 10+ business days, Expedited within 24 hours as needed
    • Will we need access to payer portals or dedicated payer integrations to submit authorizations? Options: Yes - portal/integration access provided, No - submissions via fax/email, Unknown
    • Are there financial counseling or patient cost-sharing responsibilities you want included in the auth workflow? Options: Yes - financial counseling required, Optional, No

    Coordinate Chain-of-Custody for Shipments

    • Which party currently owns chain-of-custody responsibilities? Options: Manufacturer, Site, Coordinator organization, Third-party logistics (3PL), Shared
    • What types of biological materials will require chain-of-custody tracking? Options: Fresh apheresis product, Cryopreserved cellular product, Ancillary samples (blood/tissue), Reagents/supplies
    • What cold-chain temperature classes are required for shipments? Options: Ambient, Refrigerated (2-8°C), Frozen (-20°C), Cryogenic (-80°C or LN2)
    • Do you require integration with carrier tracking or telematics for real-time location/temperature? Options: Yes - real-time telematics, Yes - carrier tracking only, No - manual confirmations
    • Is there an existing SOP for failed pickups, delays, or temperature excursions that we must follow? Options: Yes - existing SOP provided, No - require creation of SOP, Partial - need to align
    • List required shipment documentation and regulatory records for chain-of-custody (open text).
  5. Mutual Commit

    Finalize commercial and legal terms, operational responsibilities, escalation ownership, and acceptance tied to clinical milestones.

    Agreement Modules

    • Non-Disclosure Agreement (NDA)
    • Master Services Agreement (MSA)
    • Statement of Work (SOW)
    • Service Level Agreement (SLA) & Escalation Annex
    • Pricing & Payment Schedule
    • Data Processing Agreement / Business Associate Agreement (DPA/BAA)
    • Operational Responsibility Matrix (RACI)
    • Integration & Technical Onboarding Agreement
    • Clinical Acceptance & Go/No-Go Sign-off
    • Change Control / Variation Order
    • Training & Enablement Sign-off
    • Insurance, Liability & Indemnity Addendum
    • Termination & Transition Plan
    • Regulatory & Compliance Attestation
  6. Deployment

    Operationalize rollout with readiness checks, enablement, and outcome validation.

    1. Pre-Deployment Readiness

      Confirm data feeds, site access, coordinator assignments, manufacturer integrations, and contingency protocols are ready.

      Readiness Questions

      Quick Roll Call: A Two‑Minute Program Snapshot

      • Which stage best describes your program right now? Options: Feasibility / early scouting, Phase 1–2 (clinical), Phase 3 / pivotal, Commercial launch, Post‑market expansion
      • Roughly how many active patients per month are you managing through treatment timelines today? Options: 1–5, 6–20, 21–50, 51–150, 150+
      • How geographically dispersed are the sites involved in a typical patient journey? Options: Single city, Single state / metro area, Multi‑state within country, Multi‑country / global
      • Which core systems are you using today to track patient milestones? Options: EHR / EMR, CTMS, Manufacturer portal, Vendor coordination portal, Spreadsheets / email, Other
      • In one sentence, what outcome would make this program feel successful to you this quarter?

      What’s at Stake When a Timeline Breaks (and Why It Hurts)

      • If a single patient misses their treatment window tomorrow, what immediate operational and clinical consequences do you expect to see?
      • How often do you experience a missed or at‑risk treatment window today? Options: Weekly, Monthly, Quarterly, Rarely, Never tracked
      • Which downstream consequences have actually occurred from those slips? Options: Manufacturing loss / wasted product, Re‑scheduling delays > critical window, Regulatory reporting impact, Patient health impact / harm, Sponsor reputational risk, Increased costs
      • When those events happen, how do they feel internally—operationally and emotionally—for your patients and team?
      • How do you currently detect an at‑risk milestone before it becomes a missed window? Options: Automated alerts / dashboards, Manual coordinator check‑ins, Site-initiated notifications, Manufacturer notifications, We usually discover it late

      Tell Me About the Last Time It Fell Apart

      • Think of the most recent patient who fell out of sequence—what single breakdown started the cascade?
      • Which parties were directly involved in that failure? Options: Patient / caregiver, Site coordinator / research nurse, Site physician / PI, Manufacturer operations, Courier / logistics, Payer / authorization
      • How long did it take your team to realize the patient was off‑track and begin remediation? Options: Same day, 1–3 days, 4–7 days, More than a week, We still don’t know
      • What workaround or mitigation did you try, and did it resolve the issue?
      • What would you say leadership learned from that event—were any policy or process changes tried?

      Which Step Feels Like a Time Bomb?

      • If you had to pick one milestone that you’re quietly most worried about, which is it and why would it derail a patient timeline? Options: Enrollment / eligibility confirmation, Apheresis scheduling/collection, Manufacturing slot alignment, Lymphodepletion timing, Infusion scheduling, Post‑infusion follow‑up
      • Walk me through the typical touchpoints for that milestone—who communicates, what systems are used, and what manual handoffs occur?
      • What failure modes do you see there most often? Options: No‑show, Site non‑responsiveness, Manufacturer slot change, Logistics delay, Lab result delay, Documentation gap
      • How consistently do sites follow the SOPs you’ve provided for that step? Options: Always, Mostly, Sometimes, Rarely, No SOPs exist
      • Which site types or regions tend to cause the most friction? Options: Academic medical centers, Community hospitals, Dedicated apheresis centers, International sites, Satellite clinics

      Who Actually Pulls the Emergency Brake?

      • When timelines slip, who ends up making the final call to change a patient plan—your team, the site, the manufacturer, or someone else? Options: Clinical operations director, Patient services lead / coordinator, Site PI, Manufacturer operations, Joint decision (shared), Other
      • Do you have documented escalation paths and SLAs that sites and vendors acknowledge? Options: Yes — formal and signed, Partially — informal or in SOPs, No — unclear or ad hoc
      • Which roles should be notified first for an at‑risk milestone, and which actually get notified in practice?
      • How often do you find escalation ownership blurred between sponsor, manufacturer and site? Options: Very often, Sometimes, Rarely, Never tracked
      • What communication channels do sites prefer for urgent escalations (select all that apply)? Options: Phone call, SMS / text, Vendor portal alert, Email, EHR secure message

      If Zero Missed Windows Is the Goal, What Would You Need?

      • Imagine we deliver zero missed windows for six months—what measurable signals would convince your stakeholders this is real? Options: On‑time collection %, On‑time infusion %, Missed windows = 0, No‑show reduction %, Time‑to‑resolve escalations, Patient satisfaction / NPS
      • For your top two metrics above, what target values would be considered a success?
      • How would your capacity and staffing needs change if volumes doubled from trial to commercial? Options: No change, Increase coordinators moderately, Need dedicated ops team, Require automation + more staff, Unsure
      • Which internal groups must sign off that outcomes meet your definition of success? Options: Clinical ops, Medical affairs, Regulatory / QA, Commercial leadership, Manufacturing ops
      • What short‑term patient experience indicators (beyond timelines) would matter to you? Options: Caregiver burden, Patient anxiety scores, Travel burden, Communication clarity, Other

      If We Had One Week to Prove Readiness, What Would Break?

      • What is the single biggest blocker today to standing up data feeds, site access and manufacturer integrations?
      • Which integrations must be in place before go‑live (select all that apply)? Options: Manufacturer slot booking API, Site EHR interface, Lab information system, Courier tracking, Patient portal / SMS gateway, CTMS
      • Do sites typically provide technical endpoints (APIs/SFTP) or will we rely on manual file transfers and portal access? Options: APIs / automated endpoints, SFTP / scheduled files, Manual uploads / portal, Mixed—varies by site
      • What contingency protocols do you already have documented for a missed collection or delayed manufacturing window? Options: Full contingency playbook, Partial contingency plans, Ad hoc decisions only, No documented contingencies
      • What coordinator model feels realistic for your scale—dedicated for each patient, pooled regional teams, or hybrid? Options: Dedicated 1:1 coordinators, Pooled regional coordinators, Hybrid (core + dedicated for complex cases), Undecided / need guidance

      What Would a Low‑Risk Pilot Look Like to You?

      • What’s the smallest pilot that would let you validate readiness without committing full resources? Options: Single site pilot, Single patient end‑to‑end run, Regional multi‑site pilot, Integration + simulator test only
      • How quickly would you want a pilot to start once commercial and legal terms are acceptable? Options: Immediate / within 2 weeks, Within 1 month, 1–3 months, Longer than 3 months
      • Which contractual or compliance gates must be closed before we can move to pilot? Options: BAA / DPA, SOW & SLAs, Site access agreements, Manufacturer MSA / integration terms, Insurance / indemnity
      • Who are the final approvers for a pilot and what single criterion would make them green‑light it?
      • What are your biggest fears about running a pilot with an external coordination partner? Options: Loss of control over patient communication, Data security / privacy, Operational handoff failures, Hidden costs, Disruption to sites

      What Would Make You Comfortable Saying Yes?

      • What evidence, in the form of data or proof points, would most reduce your perceived risk of working with a new coordination partner? Options: Validated case studies, SLA guarantees tied to milestones, Live demo of integrations, Site references / testimonials, A short paid pilot
      • If we delivered a readiness checklist that mapped to your internal approvals, who on your team would we need to involve to finalize that checklist?
      • What timeline is acceptable for you to see measurable improvement after implementation? Options: 2–4 weeks, 1–3 months, 3–6 months, 6+ months
      • What would you want to see in a post‑pilot report to confidently transition from pilot to full deployment? Options: Milestone adherence metrics, Root‑cause analysis of exceptions, Site feedback summaries, Patient experience data, Operational playbook & runbook
      • Before we wrap, what single question have we not asked that would be important for your team to surface now?
    2. Deployment Enablement

      Schedule rollout tasks, train coordinators and sites, enable the patient portal, and establish real-time milestone tracking.

    3. Validation Checklist

      Run end-to-end dry-runs, verify timeline integrations and escalation paths, and confirm go/no-go acceptance criteria.

      Validation Questions

      Quick Snapshot: Where We Begin

      • For this program, which best describes your current stage? Options: Feasibility / Planning, Active Clinical Trial, Early Commercial Launch, Scaling Commercial Operations, Other
      • Roughly how many patients per month do you expect to coordinate across treatment milestones in the next 12 months? Options: 1–5, 6–20, 21–50, 51–200, 200+
      • Which therapeutic model describes your program? Options: Autologous cell therapy, Allogeneic cell therapy, Gene therapy, Rare disease specialty therapy, Other
      • Who on your team will be the primary contact for operational coordination (role/title)?
      • What would you most like us to understand about your program before we dig in?

      When the Clock Starts Ticking

      • What if a single missed appointment could derail a patient's therapy—how close has your program come to that? Options: It has happened, We had near-misses, We’ve avoided it so far, Unsure
      • Walk me through the critical clinical windows in your treatment timeline (e.g., target apheresis date → lymphodepletion → infusion). Which are fixed vs. flexible?
      • Who currently owns timeline confirmations for each milestone (manufacturer, sponsor, site, coordinator)? Options: Manufacturer, Sponsor clinical ops, Site coordinator, Central patient coordinator, Shared/unclear
      • How do you currently surface and escalate a missed or at-risk milestone—what triggers an escalation and to whom?
      • When a timeline slips, what are the most common downstream consequences you’ve seen? Options: Manufacturing delay, Product expiration, Missed infusion window, Patient withdrawal, Regulatory reporting impact, Other
      • How stressful or emotionally taxing do these timeline risks feel for your clinical and patient-facing teams? Options: Severe, High, Moderate, Low, Not sure

      The Workflow Nobody Draws

      • What processes do you think are documented—and where are you probably flying by the seat of your pants? Options: All milestones documented, Some milestones documented, Mostly informal processes, Ad hoc / tribal knowledge
      • List every system or tool currently used to track a patient’s progress (EMR, CTMS, EDC, manufacturer portals, spreadsheets, phone).
      • How do handoffs look between each player (patient coordinator → site RN → manufacturer rep)? Describe a typical communication path and its weakest link.
      • Which milestone handoff has historically required the most manual intervention or firefighting? Options: Apheresis scheduling, Product slot booking, Lymphodepletion coordination, Infusion scheduling, Travel/logistics
      • How often do you perform an end-to-end walkthrough of the workflow with all parties involved? Options: Monthly, Quarterly, Once per program phase, Rarely / never
      • If I asked one front-line coordinator to draw the workflow on a whiteboard, what gap would we be most likely to uncover?

      The Moments That Break Everything

      • What single routine failure causes the most anxiety—no-shows, missed apheresis, site non-responsiveness, or something else? Options: Patient no-show, Missed apheresis, Site non-responsiveness, Manufacturing slot conflict, Travel disruption, Other
      • Tell a specific story of a recent failure: what happened, who noticed it, and what was the immediate outcome?
      • How often do failures occur because of communication gaps versus system/data mismatches versus resourcing issues? Options: Mostly communication gaps, Mostly system/data mismatches, Mostly resourcing, Even mix, Unsure
      • When a critical failure occurs, how quickly are clinical leaders and the manufacturer notified and what does that notification look like? Options: Immediate automated alert, Phone call within hours, Email within 24 hours, Delayed/after escalation
      • What have been the human costs—on patients and staff—when these moments happened?
      • Which of these would you accept as an objective measure of system reliability: percentage of on-time infusions, missed-windows per 100 patients, or median time-to-escation? Select up to two. Options: % on-time infusions, Missed windows per 100 patients, Median time-to-escalation, % resolved without manufacturer impact, Other

      If We Could Guarantee Zero Missed Windows

      • Imagine you could remove one guarantee-breaking risk—what would you choose and why?
      • What are the most important measurable success signals for your program (pick up to three)? Options: % on-time collections, % on-time infusions, Zero missed treatment windows, Time from apheresis to infusion, Patient satisfaction scores
      • How would your team and your leadership notice meaningful improvement—what dashboards or reports would change?
      • What operational capacity or staffing change would you need to scale from current volume to your target volume?
      • From a patient perspective, what outcomes or experiences would signal that coordination is world-class? Options: Clear schedule visibility, Single point of contact, Proactive check-ins, Fast issue resolution, Compassionate communications
      • What concerns would leadership raise if you proposed a program designed to hit these targets?

      What Would Make a Partner Truly Trustworthy?

      • What if every vendor promised fast escalation—what would make you still hesitate to hand off coordination?
      • Which partner capabilities are non-negotiable for you (select all that apply)? Options: Therapeutic-area experience, Dedicated patient coordinators, Real-time milestone tracking, Manufacturer integrations, 24/7 escalation support, Compliance and audit readiness
      • How do you validate a coordinator's clinical judgment and ability to de-escalate a situation before it becomes a missed window?
      • What SLA terms would meaningfully reduce your anxiety (response times, resolution times, notification windows)? Options: Response within 30 minutes, Resolution within 4 hours, Escalation within 1 hour, Daily status for at-risk patients, Other
      • Which verification artifacts would you require before accepting a partner operationally (runbooks, shadowing results, DR test reports)? Options: Runbooks/protocols, Shadowing sessions, Dry-run reports, SLA scorecards, Security/compliance certifications
      • Describe a past vendor relationship that felt reliable—what specific behaviors or structures made you trust them?

      The Timing and Tech Reality Check

      • If we said we could integrate timelines with your manufacturer and sites in 6 weeks, what would make you skeptical?
      • Which data feeds are currently available or planned for integration (select all that apply)? Options: EMR connectors, Manufacturer slot API, Site scheduling API, CTMS/EDC, Manual CSV/Excel feeds, None yet
      • What access barriers do we need to plan for (IT security review, contractual DPA, site IT approvals)? Options: IT security review, DPA/contracting, Site approvals, No barriers expected, Other
      • What would a successful end-to-end dry-run look like to you—what must happen and what would be a deal-breaker?
      • Which metric would you use to accept a dry-run: % milestones simulated on-time, mean time-to-escalation, or zero intervention failures? Options: % milestones simulated on-time, Mean time-to-escalation, Zero intervention failures, Other
      • Do you have sample data or pilot patients we could use for a dry-run? If yes, who owns it and how will we access it? Options: Yes—data available, Yes—requires approvals, No, need to create test cases, Unsure

      Commitment, Risks, and First Steps

      • If implementing this coordination model exposed organizational gaps, who would need to be involved to close them quickly? Options: Head of Clinical Ops, Site leadership, Manufacturing operations, IT/security, Legal/compliance
      • What timeline for pilot → validate → scale feels realistic to you, and what's driving that timeline? Options: 4–6 weeks, 2–3 months, 4–6 months, Longer than 6 months
      • What would you consider acceptable risk for a pilot (e.g., limited patient cohort, specific sites only, time-bound)? Options: <10 patients, 10–25 patients, Site-limited pilot, Time-limited only, Other
      • What are your top three concerns about engaging an external coordination partner right now?
      • Who are the decision-makers and approvers for a partnership like this, and what does each person or group care about most?
      • If we agreed on a pilot, what's the single earliest action you could commit to in the next 7 days to keep momentum? Options: Provide sample patient data, Approve pilot sites list, Initiate DPA conversation, Identify internal project lead, Other
  7. Success

    Review outcomes against success signals, capture operational learnings, and maintain a shared channel for issues and improvements.

    Success Reviews

    • Outcomes Validation Review (Monthly)
    • Operational Retrospective & Root Cause Analysis (Trigger-based / Monthly Deep Dive)
    • Playbook & SOP Update Workshop
    • Weekly Risk & Escalation Triage (Recurring)
    • Executive Success & Scaling Review (Quarterly)

    Issues & Enhancements

    • Escalate items that cannot be resolved operationally to executive or manufacturer stakeholders.
    • Stand up a short pilot or experiment to validate the highest-impact control.
    • Update the incident register with RCA findings and share with stakeholders.
    • Schedule a follow-up verification meeting on the agreed validation date.
    • Review Proposed Revisions
    • Finalize and approve operational playbook and SOP revisions that address documented failures.
    • Assign clear owners for document updates, portal changes, and training delivery.
    • Set a rollout schedule and acceptance criteria for the updated processes.
    • Publish the revised playbook and SOPs to the shared repository with version control.
    • Update portal text, checklists, and automation rules to reflect new SOPs.
    • Schedule and deliver training to coordinators and site champions before the go-live date.
    • Announce the changes to stakeholders via the shared channel and capture acknowledgements.
    • Roll Call & Review Open Escalations
    • Reduce the backlog of critical escalations and confirm immediate mitigations.
    • Ensure every high-impact escalation has an owner and a defined timeline to resolution.
    • Welcome & Objectives
    • Close or update ticket statuses in the shared channel and notify impacted parties.
    • Trigger vendor/manufacturer escalations for issues outside operational control.
    • Document any temporary mitigations and plan for permanent fixes via the retrospective process.
    • Executive Summary of Outcomes
    • Obtain executive alignment on whether success signals justify renewal or scale decisions.
    • Secure resource or budget commitments required to remediate capacity or integration gaps.
    • Ensure executives understand patient-level consequences and strategic risks tied to operational performance.
    • Produce an executive one-pager summarizing validated outcomes, risks, and recommended decisions.
    • Draft a decision memo and obtain sign-off on renewal/scale and associated budget allocations.
    • Initiate procurement or hiring plans to close approved capacity gaps.
    • Schedule follow-up checkpoints to report on investment impact against agreed KPIs.
    • Confirm whether the program met the defined success signals for the period with validated data.
    • Identify and prioritize the top operational gaps causing missed milestones.
    • Assign clear owners and timelines for corrective actions and re-validation steps.
    • Ensure the shared issues channel has ownership, SLAs, and a monitoring cadence.
    • Publish the validated monthly outcomes report with notes on any re-calculations or data corrections.
    • Assign owners and due dates for the top 3 corrective actions identified in the session.
    • Open tickets for data/integration fixes and schedule a triage with engineering within 48 hours.
    • Update the shared channel roster and monitoring cadence document.
    • Incident Recap & Timeline
    • Identify the true root cause(s) for the incident and document contributing factors.
    • Agree on a set of prioritized corrective controls and experiments with owners and timelines.
    • Define measurable verification criteria and monitoring to ensure the fix is effective.
    • Create and assign corrective action tickets with SLOs and expected verification dates.
    • Success Signals Dashboard Review
    • Priority Sorting & Reassignment
    • Map Changes to Roles & SLAs
    • Impact Assessment
    • Patient & Clinical Impact Narrative
    • Financial / Contractual Implications
    • Update Escalation Flows & Responsibilities
    • Data Validation & Anomalies
    • Immediate Mitigations
    • Root Cause Analysis (5-Whys / Fishbone)
    • Scalability & Capacity Readiness
    • Data & System Alerts Review
    • Patient Case Spotlights
    • Technology & Portal Content Alignment
    • Preventive Controls & Experiments
    • Training & Rollout Plan
    • Strategic Risks & Mitigation Plan
    • Escalation to Execs/Manufacturers
    • Verification & Monitoring Plan
    • Gap Analysis & Root Causes (high-level)
First-Party AI

1-2 minutes please — Your AI agent is working

First-Party AI™ can make mistakes. Always check important information.